5% hydrogenated coconut oil; 10KJ%, 39.7% fructose; 2% (w/w) cholesterol), plus fructose-sucrose in drinking water (12.6%: 55:45) for 30 weeks. At sacrifice, parameters of insulin resistance (IR) and liver function, intrahepatic lipid accumulation, inflammation, fibrosis, oxidative stress, and transcript levels related to fat metabolism, fibrogenesis, fibrolysis, inflammation,

and mac-rophage polarization, as well as proinflammatory cytokines in adipose tissue were analyzed by IHC and quantitative RT-PCR. Results: Mice on the NSD developed a significant increase in body weight, fat deposition, selleck compound IR, liver weight, hepatic ste-atosis, hepatocyte ballooning, and inflammation (NAS score, 4), serum parameters of liver injury, and the level of fibrosis (Ishak score, 3). Their livers showed a significant

upregulation of transcripts related to fibrosis and fibrogenesis (procollagen α1(I), α-SMA, TGFβ1, integrin β6, PDGFRβ, PAI-1, osteopontin, TIMP-1, MMP-2), inflammation (TNFα), M1 macrophage polarization (CCL5), fibrolysis (MMP-8 and MMP-13) and a significant upregulation of genes related to M2 macrophage polarization (MCP-1). Several transcripts related to fat metabolism were also significantly elevated (PPARγ and LPL). The visceral fat of NSD mice displayed a significant upregulation of IL-6 and TNFα expression. In livers, a high IHC expression of oxidative stress related 4-hydroxynonenal and the M2 related YM-1 was found. Conclusion: In this study, we describe the Proteases inhibitor pattern of proinflammatory cytokine/chemokine expression in fat and liver tissue from a novel diet-induced NASH model. This model appears to mimic major aspects of severe human NASH, including

an unfavourable polarization and inflammatory activation of liver and visceral adipose tissue macrophages. Disclosures: Detlef Schuppan – Consulting: Boehringer Ingelheim, Aegerion, Gilead, Gen-zyme, GSK, Pfizer, Takeda, Sanofi Aventis, Silence The following people have nothing to disclose: Yong Ook Kim, Rambabu Surabattula, Kyoung-Sook Park, Shih-yen Weng Background: Currently, the therapeutic selleck products armamentarium to treat Non-alcoholic steatohepatitis (NASH) is limited. Aldosterone plays a role in hepatic fibrogenesis and its modulation could be beneficial for NASH. Aim: To investigate whether eplere-none, a mineralocorticoid receptor antagonist, modulate liver damage in experimental NASH. Methods: C57bl6 mice were fed a choline-deficient amino acid–defined (CDAA) diet for 22 weeks with or without eplerenone supplementation. Serum levels of aminotransferases and aldosterone were measured and hepatic steatosis, inflammation, and fibrosis scored histologi-cally.